Hummingbird Bioscience IPO

hummingbirdbioscience.com

Hummingbird Bioscience, founded in 2015, is a data-driven precision biotherapeutics team discovering and developing transformative biologic medicines for hard-to-treat diseases. The Hummingbird Bioscience model combines computational and systems biology, and wet lab drug discovery in a multi-disciplinary, collaborative environment spanning initial discovery through clinical development.

Founded2015
Register for Details

For more details on financing and valuation for Hummingbird Bioscience, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Hummingbird Bioscience Ticker Symbol

Hummingbird Bioscience does not currently have an official ticker symbol because this company is still private. Register today to connect with our Private Market Specialists and learn more about new pre-IPO investment opportunities.

Hummingbird Bioscience Stock Price

The stock price for Hummingbird Bioscience will be known as it becomes public. Here are similar public companies: HealthStream (NAS: HSTM), Doximity (NYS: DOCS), Zymergen (NAS: ZY), Sight Sciences (NAS: SGHT).

Major Investors for Hummingbird Bioscience

Frazier Healthcare Partners
Decheng Capital
Novo Holdings
5Y Capital
SK Group
Affinity Asset Advisors
Ally Bridge Group
Amgen Ventures
Muirwoods Ventures
Droia Oncology Ventures
Octagon Capital Advisors
Heritas Capital

Other companies like Hummingbird Bioscience in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
 
 
Sector
Last Round Est. Valuation
$317.32MM
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$1.59B
Sector